FSD Pharma Takes a Bold Step to Tackle Unmet Medical Needs in Alcohol Misuse

FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) is proud to announce the launch of a new research and development program dedicated to tackling the unmet medical needs associated with alcohol misuse. The company is committed to creating innovative solutions and biotech treatments for a variety of neurodegenerative, inflammatory, and metabolic disorders. With this new program, FSD Pharma is taking a major step towards improving the lives of those affected by alcohol misuse.

Visiting the hospital emergency room is an all too familiar sight for those who have had too much to drink. Their impaired judgement leads to chaotic behaviour and an increased demand on the hospital staff and resources. Dealing with the inebriated, who often have high blood alcohol levels, is a challenge that the medical team must face.

Alcohol intoxication is an all too common sight in hospital emergency rooms, and I witness it during every shift. Not only does it take up a considerable amount of time and resources to manage, but it also limits the treatment options available to those suffering from alcohol use disorders. That’s why I’m thrilled to be part of FSD Pharma’s Expert Advisory Committee, and to be part of the efforts to find solutions that could accelerate recovery from alcohol-intoxication and ultimately provide better care.

Substance misuse is a pervasive challenge in many countries, including Canada, with alcohol consumption being the biggest contributor. Recent findings from the US Substance Abuse and Mental Health Services Administration’s 2021 National Survey on Drug Use and Health suggest that an alarming 46.3 million people aged 12 or older met the criteria for having a substance use disorder, with 29.5 million people having an alcohol use disorder. This is a concerning number, highlighting the need for more effective strategies to tackle this issue.

FSD Pharma is proud to announce the addition of two top experts to its Scientific and Clinical Expert Committee (SCEC). Drs. Ashwin Dhanda from the United Kingdom and Anh Lê from Canada will join the board to offer their expertise in the treatment of alcohol-related indications. With the combined clinical and scientific knowledge of their innovation-driven R&D team at Lucid, the expanded SCEC, and the expert consultant team, FSD Pharma is committed to improving the quality of life for those affected by high alcohol consumption and misuse.

Alcohol affects each of us differently- depending on a range of factors such as age, weight, sex, health status, type of alcohol, and tolerance. On average, it takes the body around an hour to metabolize one drink- equivalent to 12 ounces of beer, 5 ounces of 12% alcohol, or 1.5 ounces of 40% alcohol. However, the full process of alcohol metabolism- breaking it down and eliminating it from the body- involves complex biochemical pathways and is subject to variation depending on the individual.

Alcohol consumption can have a wide range of effects on the human brain, interfering with the communication pathways and altering the way the brain functions. This disruption to the brain’s pathways can lead to a reduction in its ability to balance, coordinate, remember, speak, and judge – all of which can result in consequences associated with poor decision making or injury.

FSD Pharma is exploring the potential of developing new treatments to limit and even reverse the negative effects of alcohol on brain function. Through its subsidiary, Lucid Psycheceuticals, the company is leveraging its expertise in pharmacology, regulatory strategy and product development to investigate the effects of alcohol on the brain, alongside its existing pipelines and research priorities in brain and inflammatory disorders, including mental health. By taking part in this pioneering field of research, FSD Pharma is striving to uncover innovative solutions to address the effects of alcohol consumption.

FSD is pleased to offer its shareholders the opportunity to purchase up to 800,000 common shares through the issuance of share purchase warrants. These warrants will be valid for 13 months, with an exercise price between $1.50 USD and $4.50 USD, giving shareholders the chance to benefit from potential future growth in the company’s stock price.

About FSD Pharma

FSD Pharma Inc. is a biotechnology company making groundbreaking strides in the development of drugs to treat a range of conditions from inflammatory diseases to mental health disorders and neurodegenerative disorders. Through its two subsidiaries, FSD BioSciences and Lucid Psycheceuticals Inc., the company is researching and developing its proprietary ultra-micronized PEA formulation, FSD201, and its two lead compounds, Lucid-Psych and Lucid-MS, respectively. With these cutting-edge treatments, FSD Pharma is revolutionizing the future of health care and providing hope to those suffering from these conditions.

Leave a Comment